PDCD1LG2 and colorectal carcinoma: Previous studies based on expression profiling of CRC demonstrated that tumors with KRAS mutations had poor infiltration of T cells and high expression of inhibitory molecules (i.e. CTLA4, PDL1, PDL2, LAG3 and TIM3) [47].